CoChat

Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications

Open access
Saracino, Dario, Dorgham, Karim, Camuzat, Agnès, Rinaldi, Daisy, Rametti-Lacroux, Armelle, Houot, Marion, Clot, Fabienne, Martin-Hardy, Philippe, Jornea, Ludmila, Azuar, Carole, Migliaccio, Raffaella, Pasquier, Florence, Couratier, Philippe, Auriacombe, Sophie, Sauvée, Mathilde, Boutoleau-Bretonnière, Claire, Pariente, Jérémie, Didic, Mira, Hannequin, Didier, Wallon, David, the French Research Network on FTD/FTD-ALS, the PREV-DEMALS and Predict-PGRN study groups, Colliot, Olivier, Dubois, Bruno, Brice, Alexis, Levy, Richard, Forlani, Sylvie, Le Ber, Isabelle · 2021 · Journal of Neurology, Neurosurgery & Psychiatry
Cited by 55

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Objective: Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in C9orf72 and GRN cohorts from presymptomatic to clinical stages. Methods: We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of C9orf72 and GRN patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical–genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index. Results: pNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. GRN patients had higher levels than C9orf72 (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In C9orf72 patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades. Conclusions: This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression. Trial registration numbers: NCT02590276 and NCT04014673.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2021-326914

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 25

  1. 10.1016/j.neuron.2011.09.011 · DOI · Paper page
  2. 10.1016/j.neuron.2011.09.010 · DOI · Paper page
  3. Valente, 2019, Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review, Alzheimers Res Ther, 11, 30, 10.1186/s13195-019-0483-2 · DOI · Paper page
  4. 10.1136/jnnp-2020-323487 · DOI · Paper page
  5. Cajanus, 2020, Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis, Ann Clin Transl Neurol, 7, 903, 10.1002/acn3.51041 · DOI · Paper page
  6. Steinacker, 2017, Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net, Amyotroph Lateral Scler Frontotemporal Degener, 18, 112, 10.1080/21678421.2016.1241279 · DOI · Paper page
  7. 10.1136/jnnp-2018-318704 · DOI · Paper page
  8. Benatar, 2020, Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS, Neurology, 95, e59, 10.1212/WNL.0000000000009559 · DOI · Paper page
  9. Benatar, 2019, Neurofilaments in pre-symptomatic ALS and the impact of genotype, Amyotroph Lateral Scler Frontotemporal Degener, 20, 538, 10.1080/21678421.2019.1646769 · DOI · Paper page
  10. Caroppo, 2015, Lateral temporal lobe: an early imaging marker of the presymptomatic GRN disease?, J Alzheimers Dis, 47, 751, 10.3233/JAD-150270 · DOI · Paper page
  11. Bertrand, 2018, Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years, JAMA Neurol, 75, 10.1001/jamaneurol.2017.4266 · DOI · Paper page
  12. 10.1136/jnnp-2020-324647 · DOI · Paper page
  13. 10.1212/WNL.0000000000006344 · DOI · Paper page
  14. 10.1136/jmedgenet-2011-100699 · DOI · Paper page
  15. Cammack, 2019, Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers, Neurology, 93, 10.1212/WNL.0000000000008359 · DOI
  16. Preische, 2019, Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease, Nat Med, 25, 277, 10.1038/s41591-018-0304-3 · DOI · Paper page
  17. 10.1002/ana.24552 · DOI · Paper page
  18. Lleó, 2019, Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study, Alzheimers Dement, 15, 742, 10.1016/j.jalz.2019.01.015 · DOI · Paper page
  19. Gray, 2020, A multi-center study of neurofilament assay reliability and inter-laboratory variability, Amyotroph Lateral Scler Frontotemporal Degener, 21, 1, 10.1080/21678421.2020.1779300 · DOI
  20. Caroppo, 2014, Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin, JAMA Neurol, 71, 10.1001/jamaneurol.2014.1316 · DOI · Paper page
  21. Sudre CH , Bocchetta M , Heller C , et al . White matter hyperintensities in progranulin-associated frontotemporal dementia: a longitudinal GENFI study. Neuroimage 2019;24:102077. doi:10.1016/j.nicl.2019.102077 · DOI · Paper page
  22. Feneberg, 2018, Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis, Neurology, 90, e22, 10.1212/WNL.0000000000004761 · DOI · Paper page
  23. Fourier, 2020, A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders, Eur J Neurol, 27, 1164, 10.1111/ene.14247 · DOI
  24. 10.1136/jnnp-2020-323541 · DOI · Paper page
  25. Le Blanc, 2020, Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers, Ann Neurol, 88, 113, 10.1002/ana.25748 · DOI

Cited by

See all 55

Metadata

Authors
Saracino, D., Dorgham, K., Camuzat, A., Rinaldi, D., Rametti-Lacroux, A., Houot, M., Clot, F., Martin-Hardy, P., Jornea, L., Azuar, C., Migliaccio, R., Pasquier, F., Couratier, P., Auriacombe, S., Sauvée, M., Boutoleau-Bretonnière, C., Pariente, J., Didic, M., Hannequin, D., Wallon, D., the French Research Network on FTD/FTD-ALS, groups, T. P.-D. A. P.-P. S., Colliot, O., Dubois, B., Brice, A., Levy, R., Forlani, S., & Le Ber, I.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2021-08-04
Volume
92
Issue
12
Pages
1278-1288
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W3188822439
Cited by
55
References
19
FWCI
3.50
Type
journal article
Language
en
Open access
hybrid
Funders
  • Programme Hospitalier de Recherche Clinique (FTLD-exome, Predict-PGRN)
  • Agence Nationale de la Recherche (ANR-PRTS PREV-DEMALS, “Investissements d’avenir” ANR-11-INBS-0011)
  • Fondation Vaincre Alzheimer (FR-17035)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. https://app.cochat.ai/papers/10.1136/jnnp-2021-326914
The paper
Saracino, D., Dorgham, K., Camuzat, A., Rinaldi, D., Rametti-Lacroux, A., Houot, M., Clot, F., Martin-Hardy, P., Jornea, L., Azuar, C., Migliaccio, R., Pasquier, F., Couratier, P., Auriacombe, S., Sauvée, M., Boutoleau-Bretonnière, C., Pariente, J., Didic, M., Hannequin, D., . . . Le Ber, I. (2021). Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2021-326914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.